{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:06:49Z","timestamp":1780049209987,"version":"3.53.1"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21\/42]) had an invasive procedure versus non-exposed women (91% [38\/42]; odds ratio: 0.11; 95% confidence interval: 0.03\u20130.35). In OS-1, more rFVIIa-exposed women (58% [22\/38]) had an invasive procedure versus non-exposed women (35% [13.3\/38]; odds ratio: 2.46; 95% confidence interval: 1.06\u20135.99). In OS-2, 17% (3\/18) of rFVIIa-exposed women and 32% (5.6\/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03\u20131.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.<\/jats:p>","DOI":"10.3390\/jcm13092656","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T03:30:49Z","timestamp":1714534249000},"page":"2656","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-5684","authenticated-orcid":false,"given":"Camila","family":"Caram-Deelder","sequence":"first","affiliation":[{"name":"Leiden University Medical Center, 2333 Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-9944","authenticated-orcid":false,"given":"Hellen","family":"McKinnon Edwards","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Copenhagen University Hospital Herlev, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7309","authenticated-orcid":false,"given":"Jarmila A.","family":"Zdanowicz","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"van den Akker","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, 2333 Leiden, The Netherlands"},{"name":"Athena Institute, Vrije Universiteit, 1081 Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Birkeg\u00e5rd","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, 2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Blatn\u00fd","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology, University Hospital Brno, and Masaryk University, 625 00 Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-2475","authenticated-orcid":false,"given":"Johanna G.","family":"van der Bom","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, 2333 Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2379-8751","authenticated-orcid":false,"given":"Giuseppe","family":"Colucci","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Clinica Sant\u2019Anna, 6924 Sorengo, Switzerland"},{"name":"University of Basel, 4001 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"van Duuren","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, 2333 Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"van Geloven","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, 2333 Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dacia D. C. A.","family":"Henriquez","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, 2333 Leiden, The Netherlands"},{"name":"Amsterdam University Medical Center, University of Amsterdam, 1105 Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-4575","authenticated-orcid":false,"given":"Marian","family":"Knight","sequence":"additional","affiliation":[{"name":"National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Korsholm","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, 2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Landorph","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, 2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Lavigne Lissalde","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital, 30900 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"},{"name":"Department of Haematology, Monash Health, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-1584","authenticated-orcid":false,"given":"Daniel","family":"Surbek","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5394","authenticated-orcid":false,"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"},{"name":"Department of Haematology, Monash Health, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1289-2849","authenticated-orcid":false,"given":"Frederic J.","family":"Mercier","sequence":"additional","affiliation":[{"name":"H\u00f4pital Antoine B\u00e9cl\u00e8re, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris Saclay, 92140 Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"ACOG Committee on Practice Bulletins (2017). Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet. Gynecol., 130, e168\u2013e186.","DOI":"10.1097\/AOG.0000000000002351"},{"key":"ref_2","first-page":"112","article-title":"Patient blood management in obstetrics: Prevention and treatment of postpartum haemorrhage. A NATA consensus statement","volume":"17","author":"Stensballe","year":"2019","journal-title":"Blood Transfus. Trasfus. Sangue"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Knight, M., Callaghan, W.M., Berg, C., Alexander, S., Bouvier-Colle, M.-H., Ford, J.B., Joseph, K.S., Lewis, G., Liston, R.M., and Roberts, C.L. (2009). Trends in postpartum hemorrhage in high resource countries: A review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth, 9.","DOI":"10.1186\/1471-2393-9-55"},{"key":"ref_4","first-page":"e106","article-title":"Prevention and management of postpartum haemorrhage","volume":"24","author":"Mavrides","year":"2016","journal-title":"BJOG"},{"key":"ref_5","unstructured":"World Health Organization (2024, February 12). WHO Recommendations: Uterotonics for the Prevention of Postpartum Haemorrhage. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/277276\/9789241550420-eng.pdf?ua=1&ua=1."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.fertnstert.2013.02.013","article-title":"Fertility rate and subsequent pregnancy outcomes after conservative surgical techniques in postpartum hemorrhage: 15 years of literature","volume":"99","author":"Gizzo","year":"2013","journal-title":"Fertil Steril"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/AOG.0b013e3181a114f7","article-title":"Predictors of failed pelvic arterial embolization for severe postpartum hemorrhage","volume":"113","author":"Sentilhes","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sanad, A.S., Mahran, A.E., Aboulfotouh, M.E., Kamel, H.H., Mohammed, H.F., Bahaa, H.A., Elkateeb, R.R., Abdelazim, A.G., El-Din, M.A.Z., and Shawki, H.E. (2018). The effect of uterine artery ligation in patients with central placenta pevia: A randomized controlled trial. BMC Pregnancy Childbirth, 18.","DOI":"10.1186\/s12884-018-1989-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.gyobfe.2015.10.010","article-title":"Emergency hysterectomy for life-threatening postpartum haemorrhage: Risk factors and psychological impact","volume":"43","author":"Michelet","year":"2015","journal-title":"Gynecol. Obstet. Fertil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.03.002","article-title":"Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolism","volume":"165","author":"Thurn","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/a-0582-0122","article-title":"Peripartum Haemorrhage, Diagnosis and Therapy. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015\/063, March 2016)","volume":"78","author":"Schlembach","year":"2018","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref_12","first-page":"e307","article-title":"The daily-practiced post-partum hemorrhage management: An Italian multidisciplinary attended protocol","volume":"168","author":"Affronti","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1076029614559773","article-title":"Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings: Recommendations From the Share Network Group","volume":"22","author":"Carvalho","year":"2016","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/trf.12550","article-title":"Evaluation and management of postpartum hemorrhage: Consensus from an international expert panel","volume":"54","author":"McLintock","year":"2014","journal-title":"Transfusion"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4266\/kjccm.2016.00787","article-title":"Recombinant Activated Factor VII as a Second Line Treatment for Postpartum Hemorrhage","volume":"32","author":"Park","year":"2017","journal-title":"Korean J. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/GRF.0b013e3181cc4378","article-title":"The use of recombinant activated FVII in postpartum hemorrhage","volume":"53","author":"Franchini","year":"2010","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/jth.12844","article-title":"Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: A multicenter, randomized, open controlled trial","volume":"13","author":"Aya","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijoa.2011.07.008","article-title":"Severe postpartum haemorrhage treated with recombinant activated factor VII in 80 Czech patients: Analysis of the UniSeven registry","volume":"20","author":"Blatny","year":"2011","journal-title":"Int. J. Obstet. Anesth."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/01.AOG.0000288515.48066.99","article-title":"Use of recombinant activated factor VII in primary postpartum hemorrhage: The Northern European registry 2000\u20132004","volume":"110","author":"Alfirevic","year":"2007","journal-title":"Obstet. Gynecol."},{"key":"ref_20","first-page":"CD005011","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","volume":"2","author":"Lin","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1177\/1076029618758956","article-title":"Standardized management protocol in severe postpartum hemorrhage: A single-center study","volume":"24","author":"Colucci","year":"2018","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1213\/ANE.0b013e3181c039e6","article-title":"Recombinant activated factor VII in obstetric hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry","volume":"109","author":"Phillips","year":"2009","journal-title":"Anesth. Analg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1915628","DOI":"10.1001\/jamanetworkopen.2019.15628","article-title":"Association of timing of plasma transfusion with adverse maternal outcomes in women with persistent postpartum hemorrhage","volume":"2","author":"Henriquez","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"McCall, S.J., Henriquez, D., Edwards, H.M., van den Akker, T., Bloemenkamp, K.W.M., van der Bom, J., Bonnet, M.P., Deneux-Tharaux, C., Donati, S., and Gillissen, A. (2021). A total blood volume or more transfused during pregnancy or after childbirth: Individual patient data from six international population-based observational studies. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0244933"},{"key":"ref_25","first-page":"CD005011","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","volume":"3","author":"Simpson","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1160\/TH08-06-0376","article-title":"Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort","volume":"100","author":"Chauleur","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2009.02007.x","article-title":"Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: Analysis of HemoRec registry data from the Czech Republic","volume":"15","author":"Salaj","year":"2009","journal-title":"Haemophilia"},{"key":"ref_28","unstructured":"Novo Nordisk A\/S (2024, February 12). NovoSeven: Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novoseven-epar-product-information_en.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMra1513247","article-title":"Postpartum hemorrhage","volume":"384","author":"Bienstock","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1213\/ANE.0000000000004422","article-title":"Assessment of coagulation by thromboelastography during ongoing postpartum hemorrhage: A retrospective cohort analysis","volume":"130","author":"Rigouzzo","year":"2020","journal-title":"Anesth. Analg."},{"key":"ref_31","first-page":"B5444","article-title":"Aetiology and treatment of severe postpartum hemorrhage","volume":"65","year":"2018","journal-title":"Dan Med J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12884-019-2499-9","article-title":"Clinical characteristics of women captured by extending the definition of severe postpartum hemorrhage with \u2018refractoriness to treatment\u2019: A cohort study","volume":"19","author":"Henriquez","year":"2019","journal-title":"BMC Pregnancy and Childbirth"},{"key":"ref_33","unstructured":"UKOSS (2024, February 12). Massive Transfusion in Major Obstetric Hemorrhage. Available online: https:\/\/www.npeu.ox.ac.uk\/ukoss\/completed-surveillance\/mtmoh."},{"key":"ref_34","first-page":"86","article-title":"The Australian and New Zealand Haemostasis Registry: Ten years of data on off-licence use of recombinant activated factor VII","volume":"13","author":"Zatta","year":"2015","journal-title":"Blood Transfus."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1541-0420.2005.00356.x","article-title":"Propensity score matching with time-dependent covariates","volume":"61","author":"Lu","year":"2005","journal-title":"Biometrics."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2656\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:02Z","timestamp":1760107082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13092656"],"URL":"https:\/\/doi.org\/10.3390\/jcm13092656","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}